Shares of Theravance Biopharma Inc. (NASDAQ:TBPH) fell 0.5% during trading on Friday . The stock traded as low as $28.57 and last traded at $28.71, with a volume of 70,302 shares traded. The stock had previously closed at $28.86.

Several brokerages have recently commented on TBPH. Evercore ISI began coverage on shares of Theravance Biopharma in a research report on Monday. They set a “buy” rating and a $41.00 price objective for the company. Zacks Investment Research downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Tuesday, August 16th. Leerink Swann reaffirmed a “buy” rating and set a $31.00 price objective on shares of Theravance Biopharma in a research report on Tuesday, August 9th. Bank of America Corp. downgraded shares of Theravance Biopharma from a “neutral” rating to an “underperform” rating in a research report on Wednesday, August 3rd. Finally, Guggenheim began coverage on shares of Theravance Biopharma in a research report on Monday, June 20th. They set a “buy” rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. Theravance Biopharma has a consensus rating of “Hold” and a consensus price target of $32.00.

The firm’s market capitalization is $1.38 billion. The stock’s 50 day moving average is $25.77 and its 200-day moving average is $21.68.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by $0.01. On average, analysts forecast that Theravance Biopharma Inc. will post ($4.03) earnings per share for the current year.

In other Theravance Biopharma news, EVP Bradford J. Shafer sold 49,122 shares of the company’s stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $27.46, for a total value of $1,348,890.12. Following the completion of the sale, the executive vice president now owns 241,686 shares of the company’s stock, valued at $6,636,697.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Brett K. Haumann sold 9,509 shares of the company’s stock in a transaction that occurred on Friday, August 19th. The stock was sold at an average price of $27.97, for a total value of $265,966.73. Following the completion of the sale, the senior vice president now directly owns 197,391 shares of the company’s stock, valued at approximately $5,521,026.27. The disclosure for this sale can be found here.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.